Joshua G Petrie1, Emily T Martin2, Rachel Truscon2, Emileigh Johnson2, Caroline K Cheng2, E J McSpadden2, Ryan E Malosh2, Adam S Lauring3, Lois E Lamerato4, Maryna C Eichelberger5, Jill M Ferdinands6, Arnold S Monto2. 1. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, United States. Electronic address: jpetrie@umich.edu. 2. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, United States. 3. Department of Microbiology and Immunology, University of Michigan, Ann Arbor, United States; Department of Internal Medicine, Division of Infectious Diseases, University of Michigan, Ann Arbor, United States. 4. Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, United States. 5. Division of Biological Standards and Quality Control, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States. 6. Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Abstract
BACKGROUND: Influenza vaccines are important for prevention of influenza-associated hospitalization. However, the effectiveness of influenza vaccines can vary by year and influenza type and subtype and mechanisms underlying this variation are incompletely understood. Assessments of serologic correlates of protection can support interpretation of influenza vaccine effectiveness in hospitalized populations. METHODS: We enrolled adults hospitalized for treatment of acute respiratory illnesses during the 2014-2015 and 2015-2016 influenza seasons whose symptoms began <10 days prior to enrollment. Influenza infection status was determined by RT-PCR. Influenza vaccination status was defined by self-report and medical record/registry documentation. Serum specimens collected at hospital admission were tested in hemagglutination-inhibition (HAI) and neuraminidase-inhibition (NAI) assays. We evaluated how well antibody measured in these specimens represented pre-infection immune status, and measured associations between antibody and influenza vaccination and infection. RESULTS: Serum specimens were retrieved for 315 participants enrolled during the 2014-2015 season and 339 participants during the 2015-2016 season. Specimens were collected within 3 days of illness onset from 65% of participants. Geometric mean titers (GMTs) did not vary by the number of days from illness onset to specimen collection among influenza positive participants suggesting that measured antibody was representative of pre-infection immune status rather than a de novo response to infection. In both seasons, vaccinated participants had higher HAI and NAI GMTs than unvaccinated. HAI titers against the 2014-2015 A(H3N2) vaccine strain did not correlate with protection from infection with antigenically-drifted A(H3N2) viruses that circulated that season. In contrast, higher HAI titers against the A(H1N1)pdm09 vaccine strain were associated with reduced odds of A(H1N1)pdm09 infection in 2015-2016. CONCLUSIONS: Serum collected shortly after illness onset at hospital admission can be used to assess correlates of protection against influenza infection. Broader implementation of similar studies would provide an opportunity to understand the successes and shortcomings of current influenza vaccines.
BACKGROUND:Influenza vaccines are important for prevention of influenza-associated hospitalization. However, the effectiveness of influenza vaccines can vary by year and influenza type and subtype and mechanisms underlying this variation are incompletely understood. Assessments of serologic correlates of protection can support interpretation of influenza vaccine effectiveness in hospitalized populations. METHODS: We enrolled adults hospitalized for treatment of acute respiratory illnesses during the 2014-2015 and 2015-2016 influenza seasons whose symptoms began <10 days prior to enrollment. Influenza infection status was determined by RT-PCR. Influenza vaccination status was defined by self-report and medical record/registry documentation. Serum specimens collected at hospital admission were tested in hemagglutination-inhibition (HAI) and neuraminidase-inhibition (NAI) assays. We evaluated how well antibody measured in these specimens represented pre-infection immune status, and measured associations between antibody and influenza vaccination and infection. RESULTS: Serum specimens were retrieved for 315 participants enrolled during the 2014-2015 season and 339 participants during the 2015-2016 season. Specimens were collected within 3 days of illness onset from 65% of participants. Geometric mean titers (GMTs) did not vary by the number of days from illness onset to specimen collection among influenza positive participants suggesting that measured antibody was representative of pre-infection immune status rather than a de novo response to infection. In both seasons, vaccinated participants had higher HAI and NAI GMTs than unvaccinated. HAI titers against the 2014-2015 A(H3N2) vaccine strain did not correlate with protection from infection with antigenically-drifted A(H3N2) viruses that circulated that season. In contrast, higher HAI titers against the A(H1N1)pdm09 vaccine strain were associated with reduced odds of A(H1N1)pdm09 infection in 2015-2016. CONCLUSIONS: Serum collected shortly after illness onset at hospital admission can be used to assess correlates of protection against influenza infection. Broader implementation of similar studies would provide an opportunity to understand the successes and shortcomings of current influenza vaccines.
Authors: Danuta M Skowronski; Naveed Z Janjua; Gaston De Serres; Anne-Luise Winter; James A Dickinson; Jennifer L Gardy; Jonathan Gubbay; Kevin Fonseca; Hugues Charest; Natasha S Crowcroft; Monique Douville Fradet; Nathalie Bastien; Yan Li; Mel Krajden; Suzana Sabaiduc; Martin Petric Journal: Clin Infect Dis Date: 2012-04-26 Impact factor: 9.079
Authors: Suzanne E Ohmit; Mark G Thompson; Joshua G Petrie; Swathi N Thaker; Michael L Jackson; Edward A Belongia; Richard K Zimmerman; Manjusha Gaglani; Lois Lamerato; Sarah M Spencer; Lisa Jackson; Jennifer K Meece; Mary Patricia Nowalk; Juhee Song; Marcus Zervos; Po-Yung Cheng; Charles R Rinaldo; Lydia Clipper; David K Shay; Pedro Piedra; Arnold S Monto Journal: Clin Infect Dis Date: 2013-11-13 Impact factor: 9.079
Authors: Suzanne E Ohmit; Joshua G Petrie; Ryan E Malosh; Alicia M Fry; Mark G Thompson; Arnold S Monto Journal: J Infect Dis Date: 2014-11-21 Impact factor: 5.226
Authors: Laura Couzens; Jin Gao; Kim Westgeest; Matthew Sandbulte; Vladimir Lugovtsev; Ron Fouchier; Maryna Eichelberger Journal: J Virol Methods Date: 2014-09-16 Impact factor: 2.014
Authors: Robert B Couch; Robert L Atmar; Wendy A Keitel; John M Quarles; Janet Wells; Nancy Arden; Diane Niño Journal: Vaccine Date: 2012-10-26 Impact factor: 3.641
Authors: William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Carolyn B Bridges; Nancy J Cox; Keiji Fukuda Journal: JAMA Date: 2004-09-15 Impact factor: 56.272
Authors: Robert B Couch; Robert L Atmar; Luis M Franco; John M Quarles; Janet Wells; Nancy Arden; Diane Niño; John W Belmont Journal: J Infect Dis Date: 2013-01-10 Impact factor: 5.226
Authors: Kuan-Ying Arthur Huang; Chris Ka-Fai Li; Elizabeth Clutterbuck; Cecilia Chui; Tom Wilkinson; Anthony Gilbert; John Oxford; Rob Lambkin-Williams; Tzou-Yien Lin; Andrew J McMichael; Xiao-Ning Xu Journal: J Infect Dis Date: 2014-01-10 Impact factor: 5.226
Authors: Min Z Levine; Emily T Martin; Joshua G Petrie; Adam S Lauring; Crystal Holiday; Stacie Jefferson; William J Fitzsimmons; Emileigh Johnson; Jill M Ferdinands; Arnold S Monto Journal: J Infect Dis Date: 2019-05-24 Impact factor: 5.226
Authors: Jordan A Stinson; Archana V Boopathy; Brian M Cieslewicz; Yichen Zhang; Nickolas W Hartman; David P Miller; Matthew Dirckx; Brett L Hurst; E Bart Tarbet; Jonathan A Kluge; Kathryn M Kosuda Journal: Vaccine Date: 2021-08-12 Impact factor: 4.169
Authors: Emily T Martin; Caroline Cheng; Joshua G Petrie; Elif Alyanak; Manjusha Gaglani; Donald B Middleton; Shekhar Ghamande; Fernanda P Silveira; Kempapura Murthy; Richard K Zimmerman; Arnold S Monto; Christopher Trabue; H Keipp Talbot; Jill M Ferdinands Journal: J Infect Dis Date: 2021-06-15 Impact factor: 5.226
Authors: Joshua D Doyle; Lauren Beacham; Emily T Martin; H Keipp Talbot; Arnold Monto; Manjusha Gaglani; Donald B Middleton; Fernanda P Silveira; Richard K Zimmerman; Elif Alyanak; Emily R Smith; Brendan L Flannery; Melissa Rolfes; Jill M Ferdinands Journal: Clin Infect Dis Date: 2021-03-15 Impact factor: 9.079
Authors: Shannon R Christensen; Sushila A Toulmin; Trevor Griesman; Lois E Lamerato; Joshua G Petrie; Emily T Martin; Arnold S Monto; Scott E Hensley Journal: J Virol Date: 2019-04-03 Impact factor: 5.103